Tags

Type your tag names separated by a space and hit enter

[Psychopharmacology of autism spectrum disorders].
Nervenarzt. 2011 May; 82(5):582-9.N

Abstract

Autism spectrum disorders (ASD) are persistent, heterogeneous conditions that display many comorbid problems. Especially maladaptive behaviours like increased irritability, aggression, impulsivity and self-injurious behaviours are perceived as enormously stressful and can interfere with interventions targeting social and communication deficits. Medication treatments focussing on troubling comorbid problems in ASD can be fundamentally ameliorative, although core features of the disorder itself cannot be sufficiently treated. While atypical antipsychotics and stimulant medication have been proven to be effective in large multisite networks of ASD, serotonin reuptake inhibitors are of limited efficacy. Novel pharmacotherapies to improve social impairment are in the early stages of research.

Authors+Show Affiliations

Klinik für Psychiatrie und Psychotherapie des Kindes- und Jugendalters, Zentralinstitut für Seelische Gesundheit , J5, 68159, Mannheim. Luise.Poustka@zi-mannheim.deNo affiliation info availableNo affiliation info available

Pub Type(s)

Comparative Study
English Abstract
Journal Article
Review

Language

ger

PubMed ID

21484169

Citation

Poustka, L, et al. "[Psychopharmacology of Autism Spectrum Disorders]." Der Nervenarzt, vol. 82, no. 5, 2011, pp. 582-9.
Poustka L, Banaschewski T, Poustka F. [Psychopharmacology of autism spectrum disorders]. Nervenarzt. 2011;82(5):582-9.
Poustka, L., Banaschewski, T., & Poustka, F. (2011). [Psychopharmacology of autism spectrum disorders]. Der Nervenarzt, 82(5), 582-9. https://doi.org/10.1007/s00115-010-3238-7
Poustka L, Banaschewski T, Poustka F. [Psychopharmacology of Autism Spectrum Disorders]. Nervenarzt. 2011;82(5):582-9. PubMed PMID: 21484169.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - [Psychopharmacology of autism spectrum disorders]. AU - Poustka,L, AU - Banaschewski,T, AU - Poustka,F, PY - 2011/4/13/entrez PY - 2011/4/13/pubmed PY - 2011/11/16/medline SP - 582 EP - 9 JF - Der Nervenarzt JO - Nervenarzt VL - 82 IS - 5 N2 - Autism spectrum disorders (ASD) are persistent, heterogeneous conditions that display many comorbid problems. Especially maladaptive behaviours like increased irritability, aggression, impulsivity and self-injurious behaviours are perceived as enormously stressful and can interfere with interventions targeting social and communication deficits. Medication treatments focussing on troubling comorbid problems in ASD can be fundamentally ameliorative, although core features of the disorder itself cannot be sufficiently treated. While atypical antipsychotics and stimulant medication have been proven to be effective in large multisite networks of ASD, serotonin reuptake inhibitors are of limited efficacy. Novel pharmacotherapies to improve social impairment are in the early stages of research. SN - 1433-0407 UR - https://www.unboundmedicine.com/medline/citation/21484169/[Psychopharmacology_of_autism_spectrum_disorders]_ L2 - https://dx.doi.org/10.1007/s00115-010-3238-7 DB - PRIME DP - Unbound Medicine ER -